Fidia S.p.A. (BIT:FDA)
0.0130
-0.0014 (-9.72%)
Apr 10, 2026, 5:35 PM CET
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.01
Revenue / Employee
150.93K
Employees
140
Market Cap
216.45K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EuroGroup Laminations | 840.54M |
| Biesse | 662.48M |
| SIT S.p.A. | 314.71M |
| Tesmec | 257.61M |
| ILPRA | 86.63M |
| Clabo | 58.10M |
| OSAI Automation System | 41.92M |
| Marzocchi Pompe | 37.95M |
Fidia News
- 11 hours ago - IOVA: Analyst Comments on FDA Rejection Impact - GuruFocus
- 12 hours ago - Why Is Plus Therapeutics Stock Gaining Friday? - Benzinga
- 12 hours ago - FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short - Benzinga
- 13 hours ago - Replimune (REPL) Faces Setback as FDA Rejects RP1 Approval Again - GuruFocus
- 13 hours ago - Replimune (REPL) Shares Decline Following FDA Letter - GuruFocus
- 14 hours ago - What's Going On With Replimune Stock Friday? - Benzinga
- 16 hours ago - Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum - International Business Times (Australia)
- 17 hours ago - Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady - Benzinga